Similar Efficacy with Use of Subcutaneous and Intravenous Immunoglobulin in CIDP and MMN: Meta-Analysis
Canadian investigators conducted a meta-analysis of published reports evaluating the efficacy and safety of subcutaneous and intravenous immunoglobulin therapy for two chronic autoimmune
neuropathies.
Going Up: What’s Behind the Growth in IVIG Demand
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
Blood Protein Therapeutics: It All Starts with the Plasma
The plasma donor is the first vital part of the process to produce safe and effective plasma protein therapeutics, and the industry prioritizes the safety and health of its plasma donors.
Single IVIG Infusion Associated with Improved Recovery and Histopathological Profile in Rat Model of Ischemic Stroke
Turkish investigators conducted an exploratory study of IVIG usage in the experimentally induced middle cerebral artery occlusion rat stroke model.
Biomarker Found in CIDP Patients Who Don’t Respond to IVIG Therapy
A recent study discovered a biomarker in chronic inflammatory demyelinating polyneuropathy patients that explains why they don’t respond to intravenous immune globulin therapy.
FDA Approves NUWIQ to Treat Hemophilia A
The U.S. Food and Drug Administration ha approved Octapharma’s NUWIQ, antihemophilic factor (recombinant), an intravenous therapy for adults and children living with hemophilia A.
